Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations

Author:

Jones Steve,Flewett Maxine,Flewett Ron,Lee Sharon,Vick Bill,Thompson Milla,Pinnetti Sabine,Zoz Donald F.,Hoffmann-Vold Anna-Maria,Kreuter MichaelORCID,Maher Toby M.ORCID

Abstract

BackgroundPatient recruitment and retention are a challenge when conducting clinical trials in patients with pulmonary fibrosis, including idiopathic pulmonary fibrosis and other interstitial lung diseases. This study aimed to understand and address the barriers associated with trial participation for these populations.MethodsNine patients, nine caregivers and three healthcare professionals participated in virtual simulations of planned phase III trials. During the simulations, participants received information about the trials and either tested a home spirometry device or watched a home spirometry demonstration, before providing their insights in debriefs. The findings were interpreted in advisory boards with representatives from patient organisations and expert investigators.ResultsRegarding barriers to participation, patient fatigue and breathlessness were emphasised as posing challenges for travel, visit length and completion of onsite assessments. Lack of information, support and appreciation were also identified as factors that may exacerbate anxiety and negatively affect participant retention rates. Feedback on the home spirometry was mixed, with participants appreciating being able to complete the test at home but worrying about device handling. Based on the insights gained, patient-friendly adaptations were made to the trial protocol and conduct, including remote assessment of patient-reported outcomes, increased visit flexibility, travel support services, patient and caregiver information campaigns, and training of investigators on patients’ needs.ConclusionsParticipants identified important barriers to participation, which led to patient-friendly changes being made to the planned trials. As a result, participation in the planned trials should be less burdensome, with improved recruitment and retention rates, and ultimately, improved data quality.

Funder

Boehringer Ingelheim

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes;Haerry;Front Med,2018

2. Patient involvement in the design of a patient-centered clinical trial to promote adherence to supplemental oxygen therapy in COPD;Holm;Patient,2016

3. Partnering with patients in the development and lifecycle of medicines: a call for action;Hoos;Ther Innov Regul Sci,2015

4. Patient Focused Medicines Development . Integrating the voice of the PATIENT across the lifecycle of medicine. 2023. https://learning.pfmd.org/6/about-us/1 Date last accessed: 1 April 2023.

5. Fibrosing interstitial lung diseases: knowns and unknowns

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3